Get the latest news from ASH 2019

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tisotumab vedotin shows promise in recurrent, metastatic cervical cancer

Publish date:: March 26, 2019

Key clinical point: Tisotumab vedotin shows encouraging activity and tolerability in heavily pretreated recurrent or metastatic cervical cancer.

Major finding: ORR in 55 cervical cancer patients was 35%, confirmed ORR was 22%.

Study details: A phase 1/2a expansion study of 55 patients

Disclosures: The innovaTV 201 trial is sponsored by Genmab A/S. Dr. Hong reported having no disclosures.

Citation:

Hong DS et al. SGO 2019, Abstract 19.

This Week's Must Reads

New evidence further supports starting CRC screening at age 45,

PT-Cy bests conventional GVHD prophylaxis,

Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL,

Adjuvant denosumab falls short in early-stage breast cancer,

Single-Fraction Spine Stereotactic Radiosurgery is Cost-Efficient,

Must Reads in Gynecologic Cancer

Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancer,

In recurrent ovarian cancer, secondary surgery does not extend survival,

Surgical staging improves cervical cancer outcomes,

Sentinel node biopsy safe for women with vulval cancer,

HER2-Positive Solid Tumors: Molecule Exhibits Antitumor Activity,

Menu Close